In today’s session Qiagen NV (QGEN) registered an unusually high (510) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious QGEN increase. With 510 contracts traded and 12814 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: QGEN161118C00025000 closed last at: $3.3 or 5.7% down. About 94,445 shares traded hands. Qiagen NV (NASDAQ:QGEN) has risen 23.46% since March 2, 2016 and is uptrending. It has outperformed by 15.20% the S&P500.
Analysts await Qiagen NV (NASDAQ:QGEN) to report earnings on October, 26. They expect $0.28 earnings per share, up 3.70% or $0.01 from last year’s $0.27 per share. QGEN’s profit will be $67.14 million for 24.50 P/E if the $0.28 EPS becomes a reality. After $0.24 actual earnings per share reported by Qiagen NV for the previous quarter, Wall Street now forecasts 16.67% EPS growth.
Qiagen NV (NASDAQ:QGEN) Ratings Coverage
Out of 9 analysts covering Qiagen (NASDAQ:QGEN), 4 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 44% are positive. $33 is the highest target while $20 is the lowest. The $26.80 average target is -2.33% below today’s ($27.44) stock price. Qiagen has been the topic of 13 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The rating was maintained by Citigroup on Tuesday, March 15 with “Neutral”. The firm earned “Hold” rating on Thursday, November 12 by Stifel Nicolaus. Barclays Capital maintained the shares of QGEN in a report on Thursday, July 30 with “Overweight” rating. The firm earned “Neutral” rating on Thursday, July 30 by Mizuho. The rating was initiated by Morgan Stanley on Tuesday, September 15 with “Overweight”.
According to Zacks Investment Research, “Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.”
QIAGEN N.V. is a holding company. The company has a market cap of $6.58 billion. The Firm and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. It has a 54.95 P/E ratio. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
QGEN Company Profile
QIAGEN N.V. (QIAGEN), incorporated on April 29, 1996, is a holding company. The Firm and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. The Company’s solutions support over 500,000 clients across the world in generating insights into the molecular building blocks of life. The Company’s over two billion biological samples have been prepared or analyzed using QIAGEN sample technologies. The Company’s sample technologies are used in isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. The Company’s assay technologies make these biomolecules visible for analysis, such as identifying the DNA of a virus or a gene mutation in a tumor. The Company’s bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms tie these together in molecular testing workflows – from Sample to Insight. The Company’s Sample to Insight molecular technologies are applicable across a range of applications and customer classes through over 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Company’s bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to decide on further action. The Firm offers solutions in molecular diagnostics, applied testing, pharma and academia.
More important recent Qiagen NV (NASDAQ:QGEN) news were published by: Fool.com which released: “Why Qiagen NV Jumped Higher Today” on July 29, 2016, also Fool.com published article titled: “1750 Reasons to Like Qiagen NV”, Prnewswire.com published: “QIAGEN N.V. to Report Second Quarter and First Half of 2016 Results” on July 14, 2016. More interesting news about Qiagen NV (NASDAQ:QGEN) was released by: Fool.com and their article: “Qiagen NV Looks for a Strong Second Half” with publication date: May 04, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.